The combination of elraglusib (9-ING-41), a potent small molecule inhibitor of GSK-3β, and gemcitabine and nab-paclitaxel ...

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia ...

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Ruben Olivares, MD, discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer.

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.

Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end ...